HCPCS Code J7193: purified Factor IX billing guide

HCPCS Code J7193 covers Factor IX (antihemophilic factor, purified, non-recombinant), billed per International Unit. It is the plasma-derived Factor IX code, used for concentrates such as AlphaNine SD. It is not the recombinant code.

Recombinant Factor IX without its own product-specific code is billed under J7195 instead. Mixing the two is a denial or a recoupment on audit. This guide covers the rest of what J7193 demands. That means per-IU unit math, JW and JZ modifiers, diagnosis pairings, home infusion rules, and MAC documentation.

Found our content helpful?

Key takeaways

HCPCS Code J7193 describes Factor IX (antihemophilic factor, purified, non-recombinant), per IU. It covers plasma-derived concentrates such as AlphaNine SD.

J7193 is not a recombinant code. Recombinant Factor IX with no product-specific code is billed under J7195, and factor IX complex is billed under J7194.

Bill the International Units administered to the patient, not the vials opened. Billing vials is the most common denial trigger for this code.

JZ reporting became mandatory on July 1, 2023. Since October 1, 2023, claims missing the required JW or JZ modifier are returned as unprocessable.

Pabau, our practice management software, keeps the infusion record and the claim in one system, so billed units match the log behind them.

HCPCS Code J7193: definition and code description

HCPCS Code J7193 is a Level II HCPCS J-code for Factor IX (antihemophilic factor, purified, non-recombinant), per IU. Outpatient facilities, physician offices, and home infusion suppliers use it to bill plasma-derived Factor IX concentrate. The patients treated have hemophilia B, also known as hereditary factor IX deficiency.

The full CMS descriptor is Factor IX (antihemophilic factor, purified, non-recombinant), per IU. The code remains active in the current HCPCS Level II file. CMS maintains the HCPCS Level II code set, publishes the annual file each fall, and applies changes from January 1, with quarterly updates in between.

Two words in that descriptor do the heavy lifting. Purified, non-recombinant means the product is fractionated from pooled human plasma. A recombinant Factor IX made in cell culture is never billed under J7193. Neither is factor IX complex, which is a multi-factor product with its own code.

J7193 code details at a glance

Use this table as a quick reference before submitting any claim for HCPCS Code J7193.

Purified, non-recombinant Factor IX: clinical background

Factor IX is a clotting protein that patients with hemophilia B lack. The condition is also called Christmas disease. Without enough Factor IX, blood does not clot properly after injury, and bleeding episodes run long enough to become dangerous.

Products billed under HCPCS Code J7193 are fractionated from pooled human donor plasma rather than grown in cell culture. Manufacturers purify the Factor IX out of that plasma and run viral inactivation and removal steps. Solvent and detergent treatment, nanofiltration, and monoclonal antibody chromatography are the usual methods.

AlphaNine SD and Mononine are the products long associated with this code. Verify current product-to-code mapping against the CMS HCPCS annual file before relying on any brand name, because manufacturers discontinue products and CMS reassigns codes.

• Indication: hemophilia B (hereditary factor IX deficiency, ICD-10-CM D67)
• Product type: plasma-derived, purified single-factor concentrate, not recombinant
• Administration settings: outpatient hospital, physician office, ambulatory infusion center, and Medicare-covered home use
• Billing trigger: drug actually administered to the patient in a billable encounter or home setting

Medicare coverage for J7193

Medicare Part B covers clotting factor products when they are medically necessary for hemophilia patients. For HCPCS Code J7193, coverage conditions include a confirmed hemophilia B diagnosis, a prescriber order, and documented medical necessity. Confirming all three before the claim goes out is what claims management software is built to do.

Coverage is subject to Local Coverage Determinations (LCDs) issued by your Medicare Administrative Contractor (MAC). Noridian and Palmetto GBA each publish MAC-specific hemophilia clotting factor billing guidance. Verify your jurisdiction’s active LCD before billing, because coverage criteria, prior authorization requirements, and documentation standards differ across MAC regions.

• Medical necessity must be supported by clinical documentation in the patient record
• For home use, Medicare Part B requires that the patient or caregiver is trained to infuse and that the product comes from a qualifying supplier
• Part B drug payment is set at ASP plus 6%. Do not quote a fixed dollar amount, because CMS updates ASP quarterly. Check the current CMS ASP Drug Pricing File.

How to bill J7193: units and IU calculation

The most consequential billing rule for HCPCS Code J7193 is the unit methodology. Bill the number of International Units actually administered to the patient, not the number of vials opened or dispensed.

MAC billing guidance from Palmetto GBA and Noridian confirms the per-IU approach. One unit of service on the claim equals one IU of Factor IX administered.

1. Confirm the dose ordered: review the prescriber’s order for the number of IUs prescribed (e.g. 2,500 IU).
2. Document IUs drawn: record the exact IUs drawn from the vial or vials and administered to the patient.
3. Record any waste: if drug remains in the vial after administration and is discarded, document the wasted IUs separately.
4. Enter units on the claim: enter the administered IUs in the units field. Enter any discarded IUs on a separate line.
5. Apply the correct modifier: JW on the discarded line when waste exists, JZ on the administered line when nothing is discarded.

Worked example: a 3,000 IU vial is reconstituted and the patient receives 2,500 IU. The remaining 500 IU are discarded. Bill two lines. Line 1 is J7193 with 2,500 units for the administered drug, carrying no waste modifier. Line 2 is J7193 with 500 units and modifier JW for the discarded drug. JZ has no place on this claim, because waste occurred.

Required modifiers: JW and JZ

CMS requires either the JW modifier or the JZ modifier on claims for separately payable drugs supplied in single-dose containers, including HCPCS Code J7193. JW has applied to discarded drug for far longer. JZ is the newer half of the pair, and reporting it became mandatory on July 1, 2023. Since October 1, 2023, claims that omit the modifier where it is required are returned as unprocessable.

The rules are set out in CMS Billing and Coding Article A55932, JW and JZ Modifier Billing Guidelines. Read the remittance advice on any J7193 denial before resubmitting, because a modifier rejection reads differently from a medical necessity denial.

Verify the current modifier rules with your MAC before submission. MAC-level billing articles often add jurisdiction-specific documentation requirements beyond the CMS baseline.

ICD-10-CM diagnosis codes that pair with J7193

Every HCPCS Code J7193 claim requires a supporting ICD-10-CM diagnosis code. The primary code is D67, but clinical context may require additional codes from the hemophilia spectrum.

Confirm these codes against the current fiscal year code set before you rely on them. Our ICD-10-CM code reference covers the wider code set, and CMS republishes the official files each October.

Reimbursement and pricing basis

Medicare prices HCPCS Code J7193 from the Average Sales Price file, at ASP plus 6% for Part B drugs. CMS refreshes ASP every quarter, so any dollar figure published in an article is stale within months. Pull the current rate from the CMS ASP Drug Pricing File for the quarter you are billing.

Clotting factor carries one payment feature that most J-codes do not. Medicare pays a furnishing fee per unit of clotting factor, on top of the ASP-based drug payment. That fee recognizes the cost of supplying and handling the product. CMS updates that fee each year, and your MAC applies it to the payment rather than asking you to bill a separate code.

Commercial payers often price from a different basis, such as a percentage of AWP or a contracted per-IU rate. Read the contract before assuming ASP logic applies to a non-Medicare claim.

Documentation requirements for J7193 claims

Documentation is what an audit actually tests, and thin records are a common reason J7193 claims fail review. The following items must be present and retrievable on request from your MAC.

• Confirmed hemophilia B diagnosis: lab results or specialist records documenting Factor IX deficiency (D67)
• Prescriber’s written order: specifying the product, dose in IU, frequency, and route of administration
• Infusion administration log: date of infusion, product name, lot number, total IU drawn, IU administered, and IU wasted
• Medical necessity letter or clinical notes: supporting the ongoing need for this specific Factor IX product
• Patient or caregiver training record (home use): documentation that the patient or caregiver is trained in infusion technique
• Insurance eligibility confirmation: eligibility checked and recorded before each dispensing cycle

MAC-specific LCDs may require additional documentation. Always review the active LCD for your jurisdiction before initiating therapy and before each billing cycle.

Home infusion billing for J7193

Medicare Part B covers purified Factor IX for home use when the patient has hemophilia B and meets medical necessity criteria. Home billing for HCPCS Code J7193 follows the same per-IU unit methodology as outpatient facility billing, but it adds supplier enrollment requirements.

Suppliers billing home-dispensed clotting factor must be enrolled through the National Supplier Clearinghouse (NSC) and hold DMEPOS accreditation where it is required. Submit claims using the CMS-1500 form or the 837P electronic claim file, with Place of Service code 12 for home. The record for each home infusion encounter must capture the product, lot number, IU dispensed, and IU returned or wasted.

• Place of Service: 12 (home) for home-dispensed clotting factor
• Claim format: CMS-1500 or 837P professional claim. No institutional type of bill applies to a supplier claim for this drug.
• Supplier must maintain records of product dispensing and any returned or wasted drug
• Prior authorization may be required by some MACs for home clotting factor. Verify with your MAC before dispensing.

Common billing errors and how to avoid them

Clotting factor claims fail for a small set of repeatable reasons. HCPCS Code J7193 has six recurring failure patterns, and a pre-submission check catches every one of them.

Sort your J7193 denials by reason code once a month. One error usually accounts for most of them. That tells you whether to fix the order template, the infusion log, or the claim build.

Related HCPCS clotting factor codes

Several adjacent J-codes cover other hemophilia clotting factor products. Knowing where HCPCS Code J7193 sits within the clotting factor code family prevents miscoding, particularly when a patient switches between product types.

Several recombinant Factor IX products carry their own codes and never belong on J7195. Rixubis is J7200, Alprolix is J7201, Idelvion is J7202, and Rebinyn is J7203. Check the product-specific list first, then fall back to J7195 only when nothing matches. The chart below runs that decision from the vial to the code line.

You can look up any of these codes using AAPC’s HCPCS code lookup before you build the claim line.

How Pabau supports hemophilia factor billing

The clotting factor record and the claim usually live in separate systems. The infusion log sits in the chart, the IU math happens in a spreadsheet, and the billing team retypes both into the claim. Every hop between those places is a chance for units and modifiers to drift.

Pabau, our practice management software, holds the clinical record and the billing record in one system. Your team records the product, the IUs drawn, the IUs administered, and the IUs discarded against the encounter itself. Those figures carry through to the claim your biller reviews, so the units on the line match the log behind them.

Eligibility checks, stored documentation, and claim status tracking sit alongside that record. Your biller still decides the codes and modifiers. They do it with the infusion detail in front of them, rather than chasing it across three systems.

Simplify hemophilia billing with Pabau

Pabau helps outpatient and home infusion providers record administered and discarded IUs alongside the documentation their MAC asks for. Cleaner claims on drug codes like J7193 follow from that.

Book a demo

Conclusion

Clotting factor claims carry more billing complexity per code than almost any other drug category. Getting HCPCS Code J7193 right starts with the product in the vial. J7193 is the purified, non-recombinant Factor IX code, so a recombinant product belongs on J7195 or on its own product code.

From there the rules are mechanical. Bill per IU administered rather than per vial. Apply JW or JZ wherever the single-dose container rules require it. Pair the claim with ICD-10-CM D67, and keep the documentation your MAC asks for.

Pabau helps outpatient practices and home infusion providers structure drug billing workflows. Fewer claims then leave with a modifier missing or a unit count nobody can evidence. To see how it handles complex J-code billing, book a demo with the team.

Continue your research

Need to understand how medical billing fits your revenue cycle? Revenue cycle management explained walks through every stage from scheduling to payment reconciliation.

Seeing repeated denials on drug claims? Denial management in healthcare covers systematic approaches to reducing claim rejection rates.

Want to understand how clean claims reduce audit risk? Medical billing compliance guide outlines documentation and submission standards that support cleaner claims.

Frequently asked questions